Download Files:
Products Details
Product Description
– HDAC-IN-31 is a potent, selective and orally active HDAC inhibitor with IC50s of 84.90, 168.0, 442.7, >10000 nM for HDAC1, HDAC2, HDAC3, HDAC8, respectively. HDAC-IN-31 induces apoptosis and cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma[1].
Web ID
– HY-144293
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C25H24N4O2
References
– [1]Cui H,et al. Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics. Eur J Med Chem. 2022 Feb 5;229:114049.
CAS Number
– 1916505-13-9
Molecular Weight
– 412.48
SMILES
– O=C(NC1=CC=CC=C1N)C2=CC=C(CN3C(/C(CCC3)=C/C4=NC=CC=C4)=O)C=C2
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;HDAC
Isoform
– HDAC1;HDAC2;HDAC3;HDAC8
Pathway
– Apoptosis;Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
